Patients’ and physicians’ perceptions and attitudes about oral anticoagulation and atrial fibrillation: a qualitative systematic review

Gemma Mas Dalmau 1*, Elisenda Sant Arderiu 2, María Belén Enfedaque Montes 3, Ivan Solà 1,4, Sandra Pequeño Saco 1 and Pablo Alonso Coello 1,4

Abstract

Background: Oral anticoagulant therapy reduces the risk of stroke in patients with atrial fibrillation, but many patients are still not prescribed this therapy. The causes of underuse of vitamin K antagonists oral anticoagulants are not clear but could be related, in part, to patients' and physicians' perceptions and attitudes towards the benefits and downsides of this treatment. The purpose of this systematic review was to evaluate and synthesize patients' and physicians' perceptions and attitudes towards the benefits and downsides of vitamin K antagonist, in order to explore potential factors related with its underuse.

Methods: We included studies that used qualitative or mixed methods and focused on patients’ and/or physicians’ perceptions and attitudes towards oral anticoagulation. We systematically searched PubMed, EMBASE, ISI WoK, and PsycINFO from their inception until May 2013. Two reviewers independently assessed the quality of the included studies and synthesized results using a thematic analysis approach.

Results: We included a total of nine studies. In four studies, the quality assessed was excellent and in five was moderate. We identified three themes that were of interest to both physicians and patients: information to reinforce anticoagulation use, balance of benefits and downsides, roles in decision-making and therapy management. Three additional themes were of interest to patients: knowledge and understanding, impact on daily life, and satisfaction with therapy. The main difficulties with the use of anticoagulant treatment according to physicians were the perceived uncertainty, need of individualised decision-making, and the feeling of delegated responsibility as their main concerns. The main factors for patients were the lack of information and understanding.

Conclusion: Physicians’ and patients’ perceptions and attitudes might be potential factors in the underuse of treatment with vitamin K antagonists. Improving the quality and usability of clinical guidelines, developing tools to help with the decision-making, enhancing coordination between primary care and hospital care, and improving information provided to patients could help improve the underuse of anticoagulation.

Keywords: Atrial fibrillation, Oral-anticoagulation therapy, Perceptions, Attitudes, Patients, Physicians, Systematic Review, Qualitative Research

* Correspondence: gmasd@santpau.cat
1Iberoamerican Cochrane Center, Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Antoni Ma Claret 167, 08025 Barcelona, Spain
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Atrial fibrillation or flutter is a common cardiac disorder. Estimated prevalence of patients with atrial fibrillation was 33.5 million people worldwide in 2010, of which 20.9 million were men and 12.6 million were women [1]. Incidence and prevalence are higher in developed countries and their estimated trends are growing due to population aging [1, 2]. Age-adjusted mortality in 2010 was 1.6 and 1.7 per 100,000 for men and women, respectively [1].

A high risk of stroke is associated with atrial fibrillation [3–5]. Of all patients that suffer an stroke 20–30% have atrial fibrillation [6]. Age, a history of previous embolism, heart failure, type 2 diabetes mellitus, hypertension arteriopathy, and female sex are factors that increase the risk of embolism among patients with atrial fibrillation [7, 8]. Atrial fibrillation is a health issue that is costly for the healthcare system. Costs derive mainly from hospital admissions (50%) and treatment prescription (20%) [9]. Moreover, non-treated patients experience more complications compared to treated patients leading to obvious economic consequences [10].

Vitamin K antagonists oral anticoagulants (VKAs) significantly reduce the risk of stroke in patients with atrial fibrillation [8, 11], and are the main group of drugs that has been historically used for such patients. Nevertheless, treatment with VKAs is relatively complex due to its narrow therapeutic range, which urges regular monitoring of the International Normalised Ratio to place the patient within the optimal range for anti-thrombotic protection without excessive risk of haemorrhage [6, 12]. Furthermore, VKAs show various drug interactions and, therefore, no big changes are to be made in the intake of vitamin K-rich foods. Such specificities of the treatment with VKAs are some of the potential reasons for its underuse [13–17] despite concluding evidence available on its potential net benefit [12, 18].

A new group of oral anticoagulants has recently emerged as a therapeutic alternative for patients with atrial fibrillation: the direct oral anticoagulants (DOACs). Patients taking DOACs show lower risk of stroke, intracranial bleeding, haemorrhage or death, but higher risk of gastrointestinal bleeding compared to patients receiving VKAs [19]. Additionally, patients taking DOACs show fewer interactions with other drugs and no interactions with food. However, their effect has a shorter duration, there is no known antidote and are not recommended for patients with an important kidney condition. Moreover, DOACs are considerably more expensive than VKAs, which is an essential feature to ensure equal access and treatment adherence [20]. Although the absence of laboratory monitoring for DOACs might be attractive for patient, it also entails potential disadvantages, such as the inability to measure the level of anticoagulation, determine treatment adherence, or detect potential drug interactions [21]. Nowadays, VKAs continue to be the group of drugs more frequently used in the common practice for patients with atrial fibrillation [22].

Previous studies show that preferences of patients’ with atrial fibrillation may be an important reason for underutilization of oral anticoagulation [23–25]. The previous systematic review [25] that examined experiences of patients and health providers regarding atrial fibrillation and treatment with VKAs, revealed a few factors that might be related to underutilization of VKAs. Nevertheless, there is no qualitative systematic review to date focused on knowing patients’ and physicians’ perceptions and attitudes towards VKAs that might be potential factors for underutilization of VKAs for atrial fibrillation.

The objective of this qualitative systematic review is to identify potential factors associated with underuse of VKAs oral anticoagulants. To do so, we critically synthesized the available qualitative research evidence about patients’ and physicians’ perceptions and attitudes towards this treatment alternative.

Methods
We conducted a systematic review to synthesize findings from studies that assessed patients’ and physicians’ attitudes and perceptions of the risks, benefits, and use of vitamin K antagonists oral anticoagulants (VKAs), in order to explore the perceptions and attitudes related to the underuse of anticoagulation in patients with atrial fibrillation.

Design
Systematic review of qualitative research.

Data sources
We searched PubMed, EMBASE, ISI Web of Knowledge (ISI WoK) and PsycINFO from their inception until May 2013. In order to identify relevant publications, a search using a combination of key words “values or preferences”, “anticoagulants”, and “atrial fibrillation” was performed. The search strategy used is in Additional file 1.

Study selection
Two authors independently assessed the references retrieved from the search and later resolved any disagreements. We included: i) original articles that explored the perceptions and attitudes of patients, physicians, or both, about VKAs for atrial fibrillation; ii) used qualitative or mixed methods; and iii) were published in English, Spanish, German, or French. We excluded studies that only explored perceptions and attitudes
of health professionals other than physicians, and studies that did not include qualitative results.

Critical appraisal
We assessed the quality of studies using the Critical Appraisal Skills Programme (CASP) tool for qualitative studies [26].

Data extraction and data synthesis
We collected the main characteristics of each study included in the review (Table 1). We contacted the authors of the included studies for clarification. We used a thematic analysis to analyze the data [27]. The main and recurrent themes, as well as categories, across the studies were collected systematically. We segmented the themes and contrasted them between studies, collapsing and refining the categories per type of participant (patients and physicians) until the final result was deemed optimal.

Results
We initially retrieved 1147 references. A total of 1134 publications were excluded after reading the title and abstract, and 4 were excluded after reading the full text (Fig. 1). A total of nine articles corresponding to eight studies were included [28–36]. We also included a still unpublished study conducted by our group [37]. Two of the nine studies collected data both from patients and physicians [29, 31, 37], four collected data from patients only [28, 32, 33, 35], and three from physicians only [31, 34, 36]. In four studies, the quality assessed was excellent [29–31, 35, 37] and in five was moderate [28, 32–34, 36].

Physicians’ perceptions and attitudes
The five studies with physicians as participants [29, 31, 34, 36, 37] (Table 1) included a total of 91 physicians (family physicians, cardiologists, geriatrics and internal medicine physicians). The three main themes that emerged from the analysis were: I) information to reinforce anticoagulation use; II) balance of benefits and downsides; and III) roles in decision-making and therapy management (Fig. 2).

Information to reinforce anticoagulation use
The information needed to reinforce the vitamin K antagonists (VKA)s use was a theme that emerged in all five studies including physicians as participants [29, 31, 34, 36, 37].

In three studies [29, 31, 37], some physicians considered the scientific evidence about VKAs was a possible barrier for the correct management of anticoagulation due to the constant changes in the literature [31]. Some expressed concerns and others justified the prescription of aspirin rather than warfarin [31]. Some referred to their lack of skills in using evidence-based medicine [31]. They also expressed concerns regarding the applicability of the evidence, which they considered did not include representative populations, and did not reflect daily practice [31]. Other comments referred to the need for more information to reinforce the decision to start the VKA’s [29], the finding of ambiguities in the published clinical guidelines [31], and the importance of individualized decision-making for each patient [31, 37].

In one study [37], physicians stated that they often gave more weight to their own professional experience than to research findings for decision-making in VKA’s. In relation to what information physicians should provide to patients, in one study the opinions ranged on the grade of information provided [31], although in another study there was consensus that generally the way information was given to patients was inappropriate [29] (Table 2).

Balance of benefits and downsides
Most of the studies discussed the balance of the benefits and downsides [29, 34, 36, 37]. Physicians expressed no doubts about the benefits of VKA’s [37]. In the Bajorek study [29], however, geriatricians appeared to be more focused on the risks than on the benefits. Some physicians expressed uncertainty in specific cases, such as psychiatric patients, polymedicated patients, patients that fail to attend follow up, patients at risk of falls [34, 37], the elderly, and also in certain social environments [36, 37] as alcoholic patients [37].

Some family physicians related their uncertainty in the decision-making of anticoagulation, not only to evidence but also to the experiences [37] and reactions manifested by the patients [29]. Some physicians attributed this patient negativity to the lack of adequate information [36] or opinions based on hearsay [31]. In one study [36], physicians’ main concerns about VKA’s were the risk of bleeding and the International Normalized Ratio monitoring.

Only in one study [31], the physicians directly raised the topic of safety. Of note, most of the physicians did not show excessive concerns about safety. Family physicians who were especially concerned about safety described a lack of clarity in the protocols on safety and in the International Normalized Ratio monitoring. Additionally they felt that often the person ultimately responsible for the treatment was unclear (Table 2).

Roles in decision-making and therapy management
In all studies [29, 31, 34, 36, 37], physicians discussed decision-making. In three studies [31, 34, 37], most physicians supported shared decision-making; however, the degree of involvement varied [34]. They stated that the clearer the evidence, the less they involved patients in
| Study | Country | Methodological approach | Technique | Analysis | Quality assessment | Participants | Number (only physicians or patients) | Sex |
|-------|---------|-------------------------|-----------|----------|-------------------|--------------|-------------------------------------|-----|
| Howitt et al. 1999 [28] | United Kingdom | Mixed: quantitative and qualitative | Structured interviews (information through email) | Thematic analysis (information through email) | moderate | -Patients | 56 | 28 men/28 women (information through email) |
| Fuller et al. 2004 [32] | United Kingdom | Mixed: quantitative and qualitative | Questionnaire and interviews | Content analysis | moderate | -Patients | 76 | (in the interviews) |
| Wild et al. 2004 [33] | United States, United Kingdom and Spain | Qualitative | Semi-structured interview | Interpretative. Thematic analysis. | moderate | -Patients | 60 | |
| Coelho Dantas et al. 2004 [35] | Canada | Qualitative | Semi-structured interview. | Interpretative. Thematic analysis (information through email). Grounded theory. | excellent | -Patients | 21 | 12 men/9 women |
| Bajorek et al. 2007, 2009 [29, 30] | Australia | Qualitative: Phenomenology | Focus groups | Thematic analysis | excellent | -Physicians | 20 | 12 men/8 women |
| Solà et al. 2009 [37] | Spain | Mixed: quantitative and qualitative | Focus groups | Content analysis | excellent | Physicians | 23 | 12 men/11 women |
| Lipman et al. 2004 [29] | United Kingdom | Qualitative | Semi-structured Interview. | Framework method | excellent | -Physicians | 11 | 15 men/8 women |
| Anderson et al. 2006 [34] | United Kingdom | Mixed: quantitative and qualitative | Questionnaire and semi-structured interview | Interpretative. Grounded theory. | moderate | -Physicians | 14 | |
| Decker et al. 2012 [36] | United States | Qualitative | Semi-structured Interview. | Content analysis | moderate | -Physicians | 23 | 18 Cardiologist (Cardiologists and internal medicine)
- Nurses practitioner |

---
Table 2 Physicians’ quotations

| Information to reinforce anticoagulation use |
|------------------------------------------------|
| … although you may have, um, read things, eventually you stick to your experience, right? You can read that statistically the probability is low but if you have face a few cases … you don’t act in the same manner.’ (Family doctor, Spain) [37]. |
| … if someone comes to you with atrial fibrillation you want to know, if he’s the average man in the street, what am I best to treat him with and that’s … that’s not answered by studies that have 80% exclusion rates.’ (Family physician, UK) [29]. |

| Balance of benefits and downsides |
|-----------------------------------|
| “… I believe that in the fibrillation treatment the benefits, I think of those moments where benefits are observed, regardless of the risk of the therapy in itself…” (Family physician, Spain) [37]. |
| “Ideally you would want to treat this lady with warfarin but in view of the recurrent falls and the subsequent risk of life-threatening haemorrhage I would opt for the lesser antithrombotic of either aspirin or clopidogrel” (Hospital family physicians, UK) [34]. |

| Roles in decision-making and therapy management |
|------------------------------------------------|
| “ Patients have wonderful trust in their GPs, which we don’t want to interfere with, but they do seem to think that the GP is going to remember and know every detail.” (Hospital pharmacist, Australia) [29]. |
| “…I’m not so much convinced that it should be on me to decide on the indications, it’s far from clear to me […] on one hand, and then, I get really angry when other specialists decide on the indication, which may be appropriate but they do it with no knowledge of the patient’s social history whatsoever…” (Family physician, Spain) [37]. |
| Decision making for who goes on warfarin is taken often by one person, monitoring of warfarin is taken by another person and in our practice people are monitored in different systems, alright and er … ongoing responsibility for patient education is nonexistent … the potential risks of warfarin to me are so large in terms of errors basically.” (Family physician, UK) [29]. |

Main themes are captured in bold

decision-making [34, 37]. In two studies, physicians stated that patients preferred to delegate to them [29, 37]. However, they stressed that patients themselves needed to assume responsibility for their management [29, 37].

Even some hospital physicians proposed daily International Normalized Ratio self-monitoring as the best option for the patient because it implies a more sustained control [37].

Family physicians also felt specialized physicians delegated responsibility of a complex therapy, traditionally assigned to hospital professionals [37]. Some family physicians disagreed on the indications for VKAs given by hospital physicians [29, 31, 37]. They considered this disagreement could be associated with the differences in approach to decision-making: primary care physicians support patient-centered decision-making, while other specialists are more disease-centered [31, 37]. They also recognized a lack of confidence and experience prescribing and controlling VKAs, and communication difficulties with other specialists in case of doubt, due to the lack of communication channels [37]. Some specialized physicians also recognized this lack of communication [36] and suggested that there should be more communication between primary care and hospitals to reach a consensus on the indications [37]. Some specialized physicians stated that they also considered non-clinical characteristics of the patients, such as psychosocial characteristics [36] (Table 2).

Table 3 Patient’s quotations

| Knowledge and understanding |
|-----------------------------|
| A 72-year-old male has a 30% chance of having a stroke regardless, but if I didn’t take the Coumadin, it would be a 70% chance of having one. So I’m taking medication to avoid the stroke (Patient, Canada) [35]. |
| There was a sticker on one of the medication boxes that said you shouldn’t take aspirin with this … but the specialist said you take half a Solprin™ … so you get sort of a conflicting thing (Patient, Australia) [30]. |

| Information to reinforce anticoagulation use |
|---------------------------------------------|
| The specialist didn’t give me this (book) … he said that you could get this book and I had to go to two pharmacists to get one … I think it could be better communication … they just gave me the book (Patient, Australia) [30]. |
| I didn’t get anything … only very sketchy in [hospital]… I haven’t received anything extra at all (Patient, Australia) [30]. |

| Impact of the therapy on daily living |
|--------------------------------------|
| ‘I had to go get the blood drawn. It was such a pain to get the paperwork from the doctor’s office and go to the lab to get it drawn, and then you have to wait to talk to the doctor on the phone. He told you whether or not to continue it or to change the dosage or what I had to do. And then you have to go back again to see if it was the proper dose. It was a pain (Patient, US) [33]. |
| I will only drink one glass of wine a day. I like a glass of wine. They say just go easy on the single malt, and stuff like that … There wasn’t any special instructions regarding diet. We like good food, and we eat a good, balanced diet. I like seafood, and I love fish, and I like the odd steak. I try to stay off butter. I’m taking Bec® just now, which I don’t really like, but I try to stay off the butter and cooking with all the white sauce, and butter sauce, and stuff like that (Patient, Canada) [35]. |

| Balance of benefits and downsides |
|-----------------------------------|
| Before anything the fact of going to the hospital so often, they are crammed with people, and you have to spend the whole afternoon there … just for simple shot […] though it’s a real sacrifice (Patient, Spain) [37]. |
| ‘With a stroke you’re finished … seen lots of my family and friends with a stroke—it’s terrible’ (Patient, UK) [32]. |

| Roles in decision-making and therapy management |
|------------------------------------------------|
| Well, then, I’ve already said I’ll accept what the doctor says. If the doctor thinks the other option is better, well then, I’ll keep the other option (Patient, Spain) [37]. |
| When I went into the [clinic] to see my doctor, they admitted me to the cardiac emergency, and they kept me there all day … I was in for just about a week. … and when I was discharged the doctors explained that they were putting me on to certain medications, and Coumadin was one of them (Patient, Canada) [35]. |

| Satisfaction with therapy |
|--------------------------|
| I think they’ve been 100%. From my cardiologist to the family physician and to the pharmacists, because they’re just amazing. (Patient, Canada) [35]. |
| I certainly get interactions with different things, but I haven’t been told … (I took) antibiotics for this bad flu that I had … no, no I hadn’t [been warned beforehand] and I was a bit surprised, but once you get the bad [NPR] reading then [the doctor] says, “Oh yeah that was caused by such and such”. But you already knew that. (Patient, Australia) [29]. |

Main themes are captured in bold
Patients' perceptions and attitudes

In the six studies that included patients [28–30, 32, 33, 35, 37] (Table 1) six main themes emerged (Fig. 2): I) knowledge and understanding; II) information to reinforce anticoagulation use; III) impact of the therapy on daily living; IV) balance of benefits and downsides; V) roles in decision-making and therapy management; and VI) satisfaction with therapy.

Knowledge and understanding

In four studies [28, 30, 33, 35] patients discussed the knowledge and understanding of VKAs, varying with patient age (it was higher among younger patients) [35], condition (lower in patients with atrial fibrillation than in those with thromboembolism), and setting (lower in patients from Spain than in patients from the United Kingdom or the
United States of America) [33]. Most patients of two studies were unaware that VKAs prevents stroke [28, 30, 35] and in one particular study they did not relate with the risk of stroke nor with atrial fibrillation [30]. They did not associate International Normalized Ratio monitoring with the risk of bleeding or stroke. Only patients who had had a stroke had full knowledge of the indications for anticoagulation [30].

Patients expressed some misconceptions, hearsay [30, 33], and myths [29] about alcohol consumption, nutrition, and concurrent medication [30, 33]. These misunderstandings were likely caused by contradictory recommendations made by other patients, caregivers, and health care professionals [30]. Some reported that they had been informed that VKAs was “a sort of rat poison” [33] (Table 3).

Information to reinforce anticoagulation use
In four studies [29, 30, 35, 37] patients discussed the information they had received to reinforce VKAs use, with variable needs on the amount of information they wanted to receive [37]. In two studies [29, 35], some patients taking VKAs considered the amount of information received was insufficient. They felt that the information should be more detailed, especially concerning drug functioning and dose adjustments [29, 30]. They requested more information about the role and importance of VKAs, and the implications in accepting this treatment, at the time of the decision-making [29]. In another study, patients considered there was a lack of both written and verbal communication [30].

Patients also manifested difficulties in applying the knowledge during the daily management of their treatment, and felt they were “on their own” [29]. They would have preferred to receive the information gradually during follow-up and to be able to check if they had understood correctly [30], increasing their confidence in its management [29, 30] (Table 3).

Impact of the therapy on daily living
In four studies [30, 33, 35, 37], the issue about the impact of therapy on daily living emerged. In one study [34], in which the participants had been taking warfarin, they discussed about the impact of VKAs and stated that it was small for most of them. Factors which most concerned patients were: daily management of VKAs [30, 33, 35, 37] (dietary restrictions, interactions with other drugs and alcohol consumption), monitoring, the risk of bleeding [30, 33, 35], the bruises that made them look older, limitations in certain activities such as sports, gardening or travelling [33]. Some patients stressed the changes they had made in their daily lives in order to manage VKAs [30, 33, 35]. Regarding monitoring, some patients stated that it provided them the feeling of greater control of the disease, while others reported that it made them feel calm. However, the more frequently the monitoring takes place, the greater the perception of the burden is [33] (Table 3).

Balance of benefits and downsides
In all the studies with patients as participants [28, 30, 32, 33, 35, 37], they discussed the benefits and downsides. The benefits that some patients associated with VKAs were: assurance of treatment success, stroke prevention [32] and a chance to live longer [28]. Patients tended to choose VKAs when they perceived a risk of stroke [28] or when they had a better understanding of the conditions associated with anticoagulation (serious and mild stroke, major bleeding, and the economic costs and disadvantages of VKAs and aspirin) [37]. In general, patients who had not taken VKAs based their opinions on experiences of family members [32, 37], friends [32], and acquaintances [37]. One study [30] showed that most patients accepted the therapy, monitoring, dose changes and compliance with the therapy. However, some patients [30] considered VKAs treatment was ineffective, and those who had not suffered a stroke or were receiving the therapy for the first time were more skeptical.

In five studies, the risks of therapy perceived by the patients were bleeding [30, 32, 33, 35, 37], hematomas [33], and other adverse effects [30]. In three studies [30, 33, 35], some patients taking VKAs explained that they had major bleeding [30, 33, 35]. Two studies [33, 35] specified that only the minority of participants had this complication. Regarding bleeding, most patients in one study [30] expressed no fear of major bleeding but others expressed anxiety [30]. In two studies some patients expressed initial fear [30, 37].

In one study [37], patients described thrombotic and hemorrhagic stroke as a complex condition with serious or irreversible effects, and they considered it was more important than major bleeding, economic costs, and the disadvantages of VKAs and aspirin. In another study, they considered that hemorrhagic stroke was a final and permanent state [32]. These perceptions were based on the experience of family members and friends [32, 37] or on their own experience [32] (Table 3).

Roles in decision-making and therapy management
In three studies, the patients discussed roles in decision-making and therapy management [30, 35, 37]. In one study [30], patients stated that anticoagulation was the responsibility of both physicians and patients; however, patients felt that they alone assumed the responsibility of therapy. In two studies, most patients acknowledged that decision-making was carried out by the physician only [35, 37]. This unilateral decision was related to: I) the patient’s high level of confidence in the physician
experience [35], II) a paternalistic physician-patient relationship in which the patients were (also) reluctant to take an active role; and III) the idea that the professionals were trained and could be more objective [37]. In one study [37], some patients adopted the position of ignorance and delegated the decision to the professional. For a small group of patients in one study, the circumstances in which this therapy was initiated, as a medical emergency, prevented any significant patient involvement [35] (Table 3).

**Satisfaction with therapy**

Satisfaction emerged in three studies [29, 30, 35]. In one study, patients recognized that their satisfaction improved when information was given to them individually and was focused on care [30]. In another study, they expressed satisfaction with primary care staff [35]. Dissatisfaction also appeared in several studies. Patients expressed dissatisfaction with the lack of information [29, 35], the quality and level of the information provided by the family physicians [30], the difficulties and costs related to monitoring [35], and health professionals’ lack of knowledge of their medical history [35] (Table 3).

**Discussion**

**Main findings**

In this systematic review evaluating patients and physicians’ perceptions and attitudes towards vitamin K antagonists (VKAs), we identified several themes which could explain the underuse of VKAs. Physicians regard uncertainty in specific cases, the need of individualized decision-making, and the delegated responsibility in decision making as the main difficulties for using VKAs, while patients noted the lack of information and understanding of VKAs therapy as their main concerns.

**Our results in the context of previous research**

Three themes – information to reinforce VKAs use, balance of benefits and downsides, and roles in decision-making and therapy management – were common to patients and physicians. The first two themes were closely related from the perspective of physicians. Some of them reported uncertainty regarding the balance between benefits and downsides of VKAs in cases such as polymedicated patients or in patients at high risk of falls [34, 37]. Despite the availability of guidelines and research evidence, some physicians considered that this information did not always clarify their doubts [31] in a treatment with narrow therapeutic margins [38]. They identified ambiguities in some of the guidelines, and stated that the included populations were not necessarily representative of the very elderly, the main candidates for anticoagulation [31]. The participant physicians suggested the development of individualized decision-making tools as a strategy to improve this uncertainty [37].

The information to reinforce VKAs use was also related with decision-making and therapy management roles, both of patients and physicians. Some of the physicians and most of the patients stated that the actual decision was generally carried out by physicians only [29, 35, 37], and that the information received was often inadequately provided [29] and insufficient [29, 35]. Moreover, in one study some family physicians felt that specialized physicians delegated the responsibility of decision making to them. These two sources of delegation were perceived by family physicians as a burden. To address patient’s delegation, the use at the point of care of interactive decision aids linked to guidelines could be a potential strategy [39]. The feeling of family physicians that specialized physicians delegated the responsibility of decision making to them could be explained by the lacking certainty about the treatment and the inadequate exchange of information between them.

A systematic review by Borg et al. that explored patients’ and health professionals’ experiences on VKAs therapy, raised the debate of the discrepancy in the perception that patients and health care professionals have about the decision-making models used in practice [25]. Patients’ experiences suggested a mixed of a paternalistic and interpretative model (the physician take the decision, considering the patient’s values and preferences), while some physicians stated that they practiced shared decision-making. Our systematic review also observed this discrepancy to some extent, suggesting that shared decision–making is not really taking place in clinical practice.

Knowledge and understanding of the therapy was an important issue that arose among patients only. One study included in our systematic review shows that the knowledge and understanding was worse in elderly patients than younger [30]. Given that most patients with atrial fibrillation are of advance age, to be able to make an informed decision, it is especially important that the information is provided and explained appropriately. Moreover, it is crucial to improve the quality of the information provided to patients because it is the main factor of dissatisfaction with the therapy [12, 27, 30]. Better information will improve understanding and is likely to increase the use of anticoagulation [37]. One of the factors that may explain why the difficulties with understanding of the anticoagulant treatment are greater for the elderly is that they generally are less educated [40], although this fact is changing.

Like one of our studies shows, patients tend to choose treatment with VKAs when they have a better understanding of the conditions associated with anticoagulation [37].
Therefore, understanding of the treatment with VKAs is essential for patients to assess the benefits and downsides based on their preferences [37].

A previous systematic review of quantitative studies that evaluated patients’ preferences for anticoagulants including direct oral anticoagulants (DOACs), agrees with our review that, considering the different anticoagulant treatments, patients’ preferences are based mainly on clinical aspects (reduction in the risk of stroke and moderate increase in the risk of bleeding). Nevertheless, whenever the different treatment options offer similar security and efficacy, convenience takes on importance for the decision making, such as once-a-day administration or no interactions with drugs or food. The need for monitorization of VKAs is sometimes perceived positively and sometimes negatively [41].

Limitations and strengths

The main limitation of our study is that we cannot confirm a relationship between the factors identified and underuse of VKAs therapy [42]. Another limitation was that there were two studies which did not only included physicians and patients as participants – nurses, pharmacist, and carers participated too. Only in some cases we were able to exclude the data coming from participants other than our target groups [29, 30, 36]. Also, in one of the studies [27] it was not always possible to differentiate between patients and physicians for some of the results reported.

The review does not include studies on patients’ perceptions and attitudes towards DOACs. Nevertheless, treatment with VKAs continues to be the main group of drugs used. Additionally, a great part of the emerging deficits in the treatment with VKAs would be applicable to the treatment with DOACs, since said deficits are more related to the healthcare systems, like the lack of information provided to patients or difficulties with the coordination between primary care and hospital care.

Finally, a potential limitation is the fact that further data sources like CINAHL have not been searched. However, we believe that this may be a minor limitation since we have searched biomedical data sources with a wider and more detailed scope.

The main strength of our review is that it is the first qualitative systematic review to specifically explore factors potentially related to the underuse of oral anticoagulation in atrial fibrillation. Moreover, our review includes two more studies [36, 37] than Borg’s systematic review [25]. Another strength of our work is the research team expertise, as it includes a multidisciplinary group of experts in oral anticoagulation therapy, Evidence-Based Medicine, and qualitative research. The group also includes several authors of one of the included studies.

Implications for practice and research

To tackle the underuse of anticoagulation there is a need to improve the quality and usability of clinical guidelines, and of the information that is provided to patients; as well as to enhance the coordination between primary care and hospital care. Linking evidence-based guidelines with decision aids could be a way forward to engage patients and physicians in shared decision-making [39]. Both guidelines and tools should be user-friendly, interactive, and based on the most rigorous evidence.

We identified some of the differences between family physicians and specialized physicians. However, further studies are needed to explore in more depth this issue. Moreover, qualitative studies evaluating the perceptions and attitudes about the direct anticoagulants should also be carried out.

Conclusion

Physicians perceived uncertainty, need of individualized decision-making, and the feeling of delegated responsibility, as their main concerns that may be related to underuse of vitamin K antagonists, while for patients the main factors were the lack of information and understanding. Improving the quality and usability of clinical guidelines, the information provided to patients (e.g. linking decision aids and guidelines), developing tools to facilitate shared decision-making, and enhancing the coordination between primary care and hospital care could help improve the underuse of this important treatment option in patients with atrial fibrillation.

Additional file

Additional file 1: Search strategy. (DOCX 17 kb)

Abbreviations

DOAC: Direct oral anticoagulant; VKA: Vitamin K antagonist

Acknowledgments

We would like to thank Ms Carolyn Newey, Ms Andrea Cervera Alepuz and Ms María Victoria Leo Rosas for their invaluable help editing the manuscript.

Funding

The study is sponsored through a governmental grant of the Instituto de Salud Carlos III, Spanish Ministry of Health (grant No. PI06/90391).

Availability of data and materials

All data are provided in the published articles [28–36], except the unpublished data (of the study of Solà et al. [37]) which can be requested from the corresponding author.

Authors’ contributions

IS conducted the literature searches. ESA and BEM screened searched results and selected the studies for inclusion. GMD, ESA, BEM and SPS analyzed the data extraction. GMD and PAC drafted the initial version. ESA, BEM, IS and SPS review critically the manuscript. All authors read and approved the final version.
Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Author details
1Iberoamerican Cochrane Center, Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Antoni Ma Claret 167, 08025 Barcelona, Spain. 2Consorci d’Atenció Primària de Salut de l’Eixample (CAPSE), CAP Casanova, Barcelona, Spain. 3Institut Català de la Salut, SAP Litoral-esquerra, Barcelona, Spain. 4CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Received: 25 May 2016 Accepted: 7 December 2016
Published online: 13 January 2017

References
1. Chugh SS, Havmoeller R, Narayanani K, Singh D, Rienstra M, Benjamin EJ, Gullum RF, Kim YH, McNulty Jr. IH, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47.
2. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142–7.
3. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.
4. Cairns JA, Connolly SJ. Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. Circulation. 1991;84(2):469–81. Review.
5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147(9):1561–4.
6. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella d, Mas Dalmau, Mas J, Merx S, Vardas P; Authors/Task Force Members, Document Reviewers. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC and endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016 Aug 27.
7. Tsai LM, Chen JH, Tiao CJ. Relation of left atrial spontaneous echo contrast with prethrombotic state in atrial fibrillation associated with systemic hypertension, idiopathic dilated cardiomyopathy, or no identifiable cause (none). Am J Cardiol. 1998;81(10):1249–52.
8. Boysen G, Connolly S, Ekeowski M, Hart R, James K, Kristler P, Kronmal R, Petersen P, Singer D. Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation Analysis of Pooled Data From Five Randomized Controlled Trials. Arch Intern Med. 1994;154(13):1449–57.
9. Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. Cost of an uninsured patient with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.
10. Casciano JP, Dotiwala ZJ, Martin BC, Kwong WJ. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. J Manag Care Pharm. 2013;19(4):302–6.
11. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–7.
12. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland Jr JC, Conti JB, Ellinor PT, Ezekias MJ, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.
13. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Soto S, Haas S, Hacke W, Lip GY, Mantovani LG, Turpie AG, van Eckels M, MIsseiwitz F, Rushton-Smith S, Kayani G, Wilkinson P, Verheugt FW, GARFIELD Registry Investigators. Risk p.14of antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013;8(5):e63479.
14. Tünler LR, Van Campen JP, Kuper M, Gjesen GJ, Koks CH, Mac Gillavry MR, van Tinteren H, Beijnen JH, Brandjes DP. Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs. Aging. 2010;27(1):39–50.
15. Burgard T, Gahl W, Teo K, McAlister F, Tsuyuki R. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000;160(4):1–6.
16. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet. 1998;352:1167–71.
17. Lip GY, Golding DJ, Nazir M, Beever DS, Child DL, Fletcher RI. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract. 1997;47(418):285–9.
18. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ, American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(Suppl):S546–925.
19. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deedwania P, Eikelboom J, Ezekowitz MD, Kamij AM, Wetz J, Lewis EM, Pankomonou A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. doi:10.1016/S0140-6736(13)63234-0. Epub 2013 Dec 4.
20. Wadhera RK, Russell CE, Piazza G. Cardiovascular page. Warfarin versus novel oral anticoagulants: how to choose? Circulation. 2014;130(22):e191–3.
21. Smith K. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation. London New Drugs Group APC/DTSC Briefing. August 2011. [cited May 2012]. Available from: www.spms.nhs.uk/wp-content/uploads/2011/08/DabigatranPSPA.pdf.
22. Larsen TB. Skjøtt F, Nielsen PB, Kjeldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.
23. Wilke T, Groth A, Pfannkuche M, Harks O, Fuchs A, Maywald U, Kohlmann T, Feng YS, Breithardt G, Bauersachs R. Oral anticoagulation under use by patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use. J Thromb Thrombolysis. 2015;40(1):97–107.
24. Wilke T, Groth A, Mueller S, Verheyen F, Linder R, Maywald U, Kohlmann T, Feng YS, Breithardt G, Bauersachs R. Oral anticoagulation under use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost. 2012;107(6):1053–65.
25. Borg Xuereb C, Shaw RL, Lane DA. Patients’ and health professionals’ views and experiences of atrial fibrillation and oral-anticoagulant therapy: a qualitative meta-synthesis. Patient Educ Couns. 2012;88(2):330–7.
26. CASP International Network. Critical appraisal skills programme (CASP). Making sense of evidence about clinical effectiveness. 2010. [cited May 2012]. http://www.casp-uk.net/checklists.
27. Cafsen B, Glenton C, Pope C. Thou shalt versus thou shalt not: a meta-synthesis of GPs’ attitudes to clinical practice guidelines. Br J Gen Pract. 2007;57(547):971–8. doi:10.3339/0601640782604820. Review.
28. Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. Br Med J. 1999;318:1324–7.
29. Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Kirsch I. Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers. Med J Aust. 2007;186(4):175–80.
30. Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Kirsch I. Balancing risk versus benefit: the elderly patient’s perspective on warfarin therapy. Pharm Pract. 2009;7(2):113–23.
31. Lipman T, Murtagh MJ, Thomson R. How research-conscious GPs make decisions about anticoagulation in patients with atrial fibrillation: a qualitative study. Fam Pract. 2004;21(3):290–8.
32. Fuller R, Dudley N, Blacktop J. Avoidance hierarchies and preferences for anticoagulation-semi-qualitative analysis of older patients’ views about stroke prevention and the use of warfarin. Age Ageing. 2004;33(6):608–11.
33. Wilt D, Murray M, Donatti C. Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain. Expert Rev Pharmacoecon Outcomes Res. 2009;9(5):467–474.

34. Anderson N, Fuller R, Dudley N. ‘Rules of Thumb’ or reflective practice? Understanding senior physicians’ decision-making about anti-thrombotic usage in atrial fibrillation. Qjm an Int J Med. 2007;100(5):263–9.

35. Dantas GC, Thompson BV, Manson JA, Tracy CS, Tracy US, Upshur REG. Patients’ perspectives on taking warfarin: qualitative study in family Practice. BMC Fam Pract. 2004;5:15.

36. Decker C, Garaialde L, Garaialde B, et al. Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians. J Multidiscip Healthc. 2012;5:129–35.

37. Alonso-Coello P, Montori VM, Sola I, Schünemann HJ, Devereaux P, Charles C, Roura M, Díaz MG, Souto JC, Alonso R, Oliver S, Ruiz R, Coll-Vinent B, Diez AI, Gich I, Guyatt G. Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians’ and patients’ perspectives: protocol for a two-phase study. BMC Health Serv Res. 2008;8:221. doi:10.1186/1472-6963-8-221.

38. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–645.e4.

39. Algoritsas T, Heen AF, Brandt L, Alonso-Coello P, Kristiansen A, Akl EA, Neumann I, Tikkinen KA, Weijden T, Elwyn G, Montori VM, Guyatt GH, Vandvik PO. Decision aids that really promote shared decision making: the pace quickens. BMJ. 2015;350:g7624.

40. Hernández Madrid A, Potpara TS, Daeges N, Chen J, Larsen TB, Estner H, Todd D, Rongioni MG, Sciaraffa E, Proclemer A, Cheggour S, Amara W, Blomstrom-Lundqvist C. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace. 2016;18(3):463–7.

41. Wilke T, Bauer S, Mueller S, Kohlmann T, Bauersachs R. Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. Patient. 2016 Jul 26.

42. Carlsen B, Norheim OF. “What lies beneath it all?”–an interview study of GPs’ attitudes to the use of guidelines. BMC Health Serv Res. 2008;8:218.

---

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit